Exenatide was the first GLP-1 receptor agonist approved for clinical use in the United States (Byetta, Amylin Pharmaceuticals) in 2005 and since then has been extensively used for T2D treatment in humans and has also shown efficacy in diabetic cats [75,76,77]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.